Sec Form 3 Filing - Huang Yang @ IceCure Medical Ltd. - 2026-03-18

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Huang Yang 2. Issuer Name and Ticker or Trading Symbol IceCure Medical Ltd. [ ICCM] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 7 HA'ESHEL ST., PO BOX 3163 3. Date of Earliest Transaction (MM/DD/YY) 03/18/2026 (Street) CAESAREA3079504 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary shares 111,468 ( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Share option (right to buy) $ 1.7 ( 3 ) ( 2 ) 12/13/2030 Ordinary shares 25,000 D Share option (right to buy) $ 3.64 ( 5 ) ( 4 ) 01/12/2032 Ordinary shares 80,668 D Share option (right to buy) $ 1.51 ( 7 ) ( 6 ) 02/19/2033 Ordinary shares 40,705 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Huang Yang 7 HA'ESHEL ST., PO BOX 3163 CAESAREA3079504 X Signatures /s/ Yang Huang 03/25/2026 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represents 111,468 RSUs granted on May 15, 2025, 25% of which vested on July 1, 2025 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, of which 41,800 RSUs have vested and 69,668 remain unvested as of March 18, 2026. ( 2 )The options were granted on December 13, 2020, 25% of which vested on December 13, 2021, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 25,000 options are fully vested. ( 3 )The options were granted with an exercise price of NIS 5.256 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.70 per share. ( 4 )The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 80,668 options are fully vested. ( 5 )The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share. ( 6 )The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 30,528 options are fully vested. ( 7 )The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.